These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36479116)

  • 1. Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors.
    Li F; Zhao S; Wei C; Hu Y; Xu T; Xin X; Zhu T; Shang L; Ke S; Zhou J; Xu X; Gao Y; Zhao A; Gao J
    Front Immunol; 2022; 13():958082. PubMed ID: 36479116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
    Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
    Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
    Das S; Valton J; Duchateau P; Poirot L
    Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model.
    Sasaki T; Sakoda Y; Adachi K; Tokunaga Y; Tamada K
    Cancer Med; 2023 Jun; 12(11):12569-12580. PubMed ID: 37031457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
    Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
    Front Immunol; 2021; 12():609421. PubMed ID: 33767695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
    Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
    J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
    Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ
    Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells.
    Niu W; Wang B; Zhang Y; Wang C; Cao J; Li J; He Y; Lei P
    Front Immunol; 2024; 15():1433679. PubMed ID: 39086477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
    Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
    J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].
    Feng DD; Chen XH; Guo JJ; Wang KK; Zhang XM; Gao JM
    Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):657-665. PubMed ID: 34289557
    [No Abstract]   [Full Text] [Related]  

  • 12. Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion.
    Luo H; Su J; Sun R; Sun Y; Wang Y; Dong Y; Shi B; Jiang H; Li Z
    Clin Cancer Res; 2020 Oct; 26(20):5494-5505. PubMed ID: 32816947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74.
    Lee IK; Noguera-Ortega E; Xiao Z; Todd L; Scholler J; Song D; Liousia M; Lohith K; Xu K; Edwards KJ; Farwell MD; June CH; Albelda SM; Puré E; Sellmyer MA
    Clin Cancer Res; 2022 Dec; 28(24):5330-5342. PubMed ID: 35972732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.
    Zhou L; Li Y; Zheng D; Zheng Y; Cui Y; Qin L; Tang Z; Peng D; Wu Q; Long Y; Yao Y; Wong N; Lau J; Li P
    Mol Ther Oncol; 2024 Jun; 32(2):200817. PubMed ID: 38882528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Construction and functional analysis of EGFRvIII CAR-T cells co-expressing IL-15 and CCL19].
    Chen W; Xian N; Lin S; Liao W; Chen M
    Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3787-3799. PubMed ID: 37805854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma.
    Meng M; Wu YC
    J Immunol Res; 2021; 2021():1782728. PubMed ID: 34527749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.
    Adachi K; Kano Y; Nagai T; Okuyama N; Sakoda Y; Tamada K
    Nat Biotechnol; 2018 Apr; 36(4):346-351. PubMed ID: 29505028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma.
    Bughda R; Dimou P; D'Souza RR; Klampatsa A
    Immunotargets Ther; 2021; 10():313-323. PubMed ID: 34386436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antitumor Study of Neoantigen-reactive T Cells Co-expressing IL-7 and CCL19 
in Mouse Lung Cancer].
    Wu D; Li C; Wang Y; He Z; Jin C; Guo M; Chen R; Zhou C
    Zhongguo Fei Ai Za Zhi; 2024 Jul; 27(7):504-513. PubMed ID: 39147704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
    Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.